Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP646031.RAwXoZKSjQL59IrnBzaQSlsoABurhmzjlB_M_UcrGhhTU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP646031.RAwXoZKSjQL59IrnBzaQSlsoABurhmzjlB_M_UcrGhhTU130_assertion type Assertion NP646031.RAwXoZKSjQL59IrnBzaQSlsoABurhmzjlB_M_UcrGhhTU130_head.
- NP646031.RAwXoZKSjQL59IrnBzaQSlsoABurhmzjlB_M_UcrGhhTU130_assertion description "[These data indicate that quantity and lytic efficiency of CD16(+) lymphocytes are major factors for ADCC induction by trastuzumab, and confirm that breast cancer responses to short-term trastuzumab monotherapy may depend on involvement of the ADCC mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP646031.RAwXoZKSjQL59IrnBzaQSlsoABurhmzjlB_M_UcrGhhTU130_provenance.
- NP646031.RAwXoZKSjQL59IrnBzaQSlsoABurhmzjlB_M_UcrGhhTU130_assertion evidence source_evidence_literature NP646031.RAwXoZKSjQL59IrnBzaQSlsoABurhmzjlB_M_UcrGhhTU130_provenance.
- NP646031.RAwXoZKSjQL59IrnBzaQSlsoABurhmzjlB_M_UcrGhhTU130_assertion SIO_000772 18089830 NP646031.RAwXoZKSjQL59IrnBzaQSlsoABurhmzjlB_M_UcrGhhTU130_provenance.
- NP646031.RAwXoZKSjQL59IrnBzaQSlsoABurhmzjlB_M_UcrGhhTU130_assertion wasDerivedFrom befree-2016 NP646031.RAwXoZKSjQL59IrnBzaQSlsoABurhmzjlB_M_UcrGhhTU130_provenance.
- NP646031.RAwXoZKSjQL59IrnBzaQSlsoABurhmzjlB_M_UcrGhhTU130_assertion wasGeneratedBy ECO_0000203 NP646031.RAwXoZKSjQL59IrnBzaQSlsoABurhmzjlB_M_UcrGhhTU130_provenance.